Sol-Gel Technologies (Sol-Gel Technologies) Short Percentage of Float

View and export this data going back to 2018. Start your Free Trial

What is Sol-Gel Technologies Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Sol-Gel Technologies's Short Percentage of Float

For the Biotechnology subindustry, Sol-Gel Technologies's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sol-Gel Technologies's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Sol-Gel Technologies's Short Percentage of Float falls into.

Sol-Gel Technologies (Sol-Gel Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sol-Gel Technologies Ltd (NAS:SLGL) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

4SG:Germany 4SG:Germany

Address

7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650

Website

https://www.sol-gel.com

Sol-Gel Technologies Ltd is a clinical-stage specialty pharmaceutical company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.